Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of IPV co-administered with PCV-free Rotarix in healthy Chinese infants
2022-000708-36Phase 3
- Sponsor
- GSK
- Start
- Jun 2023
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in rotaviral diarrhea and poliomyelitis comparing IPV + Rotarix PCV-free with IPV alone (2 arms). Primary endpoint: Seroconversion for anti-poliovirus neutralizing antibodies.
02
Drugs
human rotavirus RIX4414 strain vaccinetrivalent inactivated polio vaccine
03
Conditions
rotaviral diarrheapoliomyelitis
Beyond the preview
Go deeper on 2022-000708-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000708-36.